Profile
Thierry Darcis formerly worked at Zogenix International Ltd., as Director, Executive VP & General Manager from 2015 to 2017, Shire ViroPharma, Inc., as General Manager, and Zogenix, Inc., as Executive VP & General Manager-Europe Region from 2015 to 2017.
Dr. Darcis received his Masters Business Admin degree from the University of Stellenbosch, doctorate degree from Université Catholique de Louvain, and undergraduate degree from Solvay Business School of Economics & Management.
Former positions of Thierry Darcis
| Companies | Position | End |
|---|---|---|
| ZOGENIX, INC. | Corporate Officer/Principal | 2017-11-21 |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Director/Board Member | 2017-11-21 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Corporate Officer/Principal | - |
Training of Thierry Darcis
| University of Stellenbosch | Masters Business Admin |
| Université Catholique de Louvain | Doctorate Degree |
| Solvay Business School of Economics & Management | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Zogenix International Ltd.
Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Thierry Darcis